David Fleming

Background

About David Fleming

Documented success being a top sales performer in the Medical Capital, pharmaceutical, biotechnology, including diagnostics, cataracts and refractive arenas. • Early innovator implementing early detection early treatment programs with Retina Physicians and Optometry when Ranibizumab came to market utilizing the Foresee PHP to detect early AMD. Only rep kept on after acquisition. • One of the first Optos reps to call on Retina Surgeons. Promoted after “Rookie of the year” and 2 President Clubs and Ophthalmology Sales Manager of the year. • Presented an overview to the Nikon team in Tokyo of our technology in this growth arena. Optos became Nikons first acquisition into Medical with a 350 million purchase. • First sales rep hired at Avedro after FDA approval, developed partnership with a brand new group of KOLs. • Sold the first device in the country and implemented the first OD educational event. • Sold device to the first major pre FDA approval market share leader and initiated the blueprint to successfully implement the first orphan drug device combo with a surgical component ever in the industry. This account is still the gold standard for successful processes and procedural model. • National Sales leader 2016 and 2017 while performing dual roles, having been promoted to Director of Sales US and maintaining previous territory. • Developed business with hundreds of major healthcare institutions nationally. • Increased revenue from $20M to $40M in 2 years as National Sales Manager. • Extensive relationships and knowledge of the KOL’s within the US in every specialty. • Managed US Sales team and initiated OD development and DOD programs. • Successfully changed Avedro’s strategy from private pay to a reimbursement model in the US, resulting in significant revenue growth utilizing one internal reimbursement specialist and a team of specialists approach. • Implemented the reimbursement process of the J and CPT codes together with the sales organization and customer base. • Consulted with KOLs to help promote and educate their colleagues on Avedro technologies. • Implemented the first OD and MD combined educational event. This resulted in our core game plan of synergy between Optometry and General Ophthalmology and became the core business plan. • Increased sales force 60 % by bringing top performers from all facets of the industry to our team and didn’t lose a rep. • IPO in under three years and 500 million acquisition in under four.